Poolbeg Pharma Plc · LSE:POLB
Poolbeg Pharma — Investor Presentation (July 2023)
28 slides from Poolbeg Pharma's investor presentation, July 2023
Slide 1: Company Presentation
Company Presentation July 2023 AIM: POLB
Slide 2: Disclaimer
Disclaimer The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of engaging
Slide 3: A Clinical Stage Biopharma Company Specialising in Infectious & Other Prevalent Diseases
A Clinical Stage Biopharma Company Specialising in Infectious & Other Prevalent Diseases Becoming a ‘one-stop-shop’ for pharma and biotech seeking programmes to in-licence 3
Slide 4: Four Steps To Generating Sustainable Shareholder Value
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case Four Steps To Generating Sustainable Shareholder Value 1 Non-dilutive Acquire funding Portfolio approach – high potential Multiple shots on goal – opportunities advancing multiple drug mitigating risk opportunities programmes in paral
Slide 5: Poolbeg's Broad and Exciting Pipeline of Assets
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case Poolbeg’s Broad and Exciting Pipeline of Assets Pipeline – Clinical Development Product Candidate Pre Clinical Phase I Phase II Phase III Upcoming Catalysts POLB 001 Partnering ready Severe Influenza Treatment LPS Challenge Trial Comp
Slide 6: POLB 001
POLB 001 Potential blockbuster immunomodulator Significant opportunity across multiple disease areas Severe influenza Oncology 6
Slide 7: Potential to Block p38 MAPK Driven Cytokine Release Syndrome (CRS)
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case Potential to Block p38 MAPK Driven Cytokine Release Syndrome (CRS) Benefitting severe flu patients, CAR T cell patients and beyond Severe influenza Immune Severe influenza infections causes hypercytokinaemia, over-activation also know
Slide 8: POLB 001 – Severe Influenza
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case POLB 001 – Severe Influenza Clinical stage potential blockbuster immunomodulator Potential transformational treatment Worldwide rights for all uses in humans • Positive Phase I studies completed • Patent protected until 2038 • Safe &
Slide 9: LPS Human Challenge Trial
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case LPS Human Challenge Trial Robust positive clinical data generated – successfully met all clinical endpoints What is LPS? Trial Design • A bacterial product that mimics infection activating the immune • Randomised, double-blind, placeb
Slide 10: LPS Human Challenge Trial Results
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case LPS Human Challenge Trial Results POLB 001 Induced Significant Reductions Across Several key p38 MAPK Driven Cytokines TNF-α IL-6 IL-8 TNF-α reduction of 73.5% and 56.2% seen for IL-6 reduction of 57.4% and 63.5% seen for IL-8 reducti
Slide 11: POLB 001 - a Potent and Selective Inhibitor of p38 MAPK Signaling
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case POLB 001 - a Potent and Selective Inhibitor of p38 MAPK Signaling Demonstrates Strong Potential as a Treatment for Acute Inflammatory Conditions POLB 001 was widely distributed, reduced the inflammatory response and inhibited p38 MAPK
Slide 12: CAR T Cell Therapy causes CRS
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case CAR T Cell Therapy causes CRS CAR T Associated Toxicities Such as CRS are a Challenge in the Clinic How CAR T Cell Therapy Works POLB 001 as a CAR T cell companion therapy • Up to 95% of CAR T cell patients suffer CRS related side eff
Slide 13: Artificial Intelligence Programmes
Artificial Intelligence Programmes Unlocking the power of unique human challenge trial data Influenza RSV 13
Slide 14: Using Human Challenge Data & AI to Identify Novel Drug Targets
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case Using Human Challenge Data & AI to Identify Novel Drug Targets Building on previous target discovery with POLB 001 High Quality and Unique Supplemented with Public In Depth Analysis Novel Drug Targets & Challenge Trial Data Datasets t
Slide 15: OneThree Biotech – Clinically Validated AI
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case OneThree Biotech – Clinically Validated AI New RSV drug targets & treatments identified Poolbeg’s Partnership with OneThree Biotech Existing OneThree Biotech Clients • The goal: identify a range of targets and drugs which will amelior
Slide 16: CytoReason – World Leaders in AI
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case CytoReason – World Leaders in AI Identify new Influenza drug targets Poolbeg’s Partnership with CytoReason Existing CytoReason Clients • The goal: identify new therapeutic targets for influenza patients • Poolbeg Pharma partnered with
Slide 17: Oral Delivery Platforms
Oral Delivery Platforms Significant opportunity across multiple disease areas Vaccines Metabolic Disease 17
Slide 18: Oral Delivery Platform
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case Oral Delivery Platform Potential Applications Across Numerous Therapeutic Areas Vaccines • Poolbeg-led consortium awarded non-dilutive funding to progress Oral Vaccine Platform to a Phase I Licenced ready state by Poolbeg • Oral vacci
Slide 19: Metabolic Diseases – A Fast Growing Market
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case Metabolic Diseases – A Fast Growing Market GLP-1 Agonist market expected to exceed $150bn by 2031 Significant interest to develop therapeutics within the metabolic disease space Eli Lilly enters deal with Nimbus for metabolic disease
Slide 20: POLB 002 – Respiratory Virus Infection Immunotherapy
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case POLB 002 – Respiratory Virus Infection Immunotherapy First-in-class, broad spectrum, RNA-based Overview In vivo influenza A challenge • Late preclinical stage with extensive preclinical data package • Derived from 20 years research by
Slide 21: POLB 003 – Melioidosis Vaccine Candidate
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case POLB 003 – Melioidosis Vaccine Candidate Late preclinical stage Overview Significantly enhances survival in a model of chronic melioidosis • Burkholderia pseudomallei causes severe disease in humans • Late preclinical stage with exten
Slide 22: Investment Case
Overview POLB 001 AI Oral Delivery POLB 002 & 003 Investment Case Investment Case Poolbeg is well positioned to create sustainable shareholder value into the future 1 4 Team with Exceptional Track Record Multiple Near Term Value Inflection Points • Previously created c. $2 billion in shareholder val
Slide 23: Appendices
POOLBEG PHARMA Appendices AIM: = POLB
Slide 24: Significant progress made & continuing with strong momentum
Significant progress made & continuing with strong momentum Well capitalised with the funding to support future growth AI Deal with CytoReason & Influenza Drug Targets Identified AI Deal with OneThree Biotech & RSV drug targets & treatments identified License for RNA-Based Immunotherapy for RVIs – P
Slide 25: Additional Vaccine Candidates from UCD
Additional Vaccine Candidates from UCD Option agreement for 5 additional vaccine antigen candidates O157 E.coli/STEC/ Pseudomonas Acinetobacter Klebsiella Burkholderia VTEC aeruginosa baumannii pneumoniae cepacia complex • Lead antigen • Multiple antigens • Multiple antigens • Lead antigen • Lead an
Slide 26: Experienced Leadership Team
Experienced Leadership Team Cathal Friel Jeremy Skillington, PhD Ian O’Connell Chairman CEO CFO Prof Brendan Patrick Ashe Prof Luke O’Neill Eddie Gibson Buckley Non-Executive Non-Executive Non-Executive Non-Executive Director Director Director Director 26
Slide 27: Experienced Team to Execute
Experienced Team to Execute CMO David English Bruno Speder Carol Dalton Industry leading CMO VP, Business Development Regulatory Specialist VP, IR & PR - Expert in designing and implementing clinical trials - Over 20 years experience in pharma & biotech with drug development focus - Clinically exper
Slide 28: Stay in touch
Stay in touch www.PoolbegPharma.com @PoolbegPharma IR@PoolbegPharma.com Poolbeg Pharma AIM: POLB